Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Drug Treatment Study for Acute Ischemic Stroke
The purpose of this study is to determine whether treatment with the neuroprotectant drug, NA-1, will reduce long-term disability in patients who have an acute ischemic stroke and who are undergoing thrombectomy. Nationwide, 1120 patients will be recruited for this study. At Rush University, we expect to recruit 20 patients. Treatment assignment will be assigned randomly between NA-1 and a placebo.
In order to participate you must meet the following criteria:
- Are 18 years of age or older.
- Have an onset (last-seen-well) time to randomization time within 12 hours.
- Have a disabling stroke defined as a baseline NIHSS > 5 at the time of randomization.
- Have pre-stroke (24 hours prior to stroke onset) independent functional status in activities of daily living with modified Barthel Index (BI) > 90 (95 or 100).
You will be excluded from the study if any of the following criteria apply to you:
- Have evidence of a large core of established infarction defined as ASPECTS 0-4.
- Have evidence of absence of collateral circulation on CTA (Collateral score of 0 or 1).
- Have estimated or known weight > 120 kg or < 45 kg.
- Have severe known renal impairment defined as requiring dialysis or if known creatinine clearance < 29 mL/min.
This is a partial list of inclusion and exclusion criteria.